| 4 | 0 | 9 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 分析早期和晚期乳腺癌患者的诊疗费用，为乳腺癌临床诊疗及卫生政策制定提供依据。方法 回顾性收集包头医学院第一附属医院2020年8月至2024年10月收治的323例女性乳腺癌患者的基本情况、诊疗信息、医疗费用等资料，分析早期和晚期乳腺癌患者的诊疗费用。结果323例乳腺癌患者的年龄为25～90岁[（53.34±10.19）岁]，其中早期279例（86.38%），晚期44例（13.62%）；诊疗费用为38 246.92(23 211.46,66 060.00)元/例，其中早期患者诊疗费用为37 069.00(23 675.73 , 60 250.17)元/例，晚期患者诊疗费用为50 926.59(20 544.98,96 406.90)元/例。由城镇职工医疗保险报销后，晚期乳腺癌患者所承担的经济负担为11 471.27(8 089.30, 14 853.25)元/例，直接医疗费用占年人均可支配收入的20.1%；而早期乳腺癌患者所承担的经济负担更低，为8 288.48(7 289.85,9 287.12)元/例。由城镇居民医疗保险报销后，晚期乳腺癌患者所承担的经济负担相对较重，为22 942.55(16 178.60, 29 706.50)元/例，直接医疗费用占年人均可支配收入的40.2%；而早期乳腺癌患者所承担的经济负担为16 576.97(14 579.71,18 574.23)元/例。若患者为自费，晚期乳腺癌患者所承担的经济负担占年人均可支配收入的134.1%，早期乳腺癌患者所承担的经济负担占年人均可支配收入的96.9%。结论乳腺癌诊疗费用占人均可支配收入比例较高，未来需加强乳腺癌防治以减轻患者经济负担。
Abstract：Objective To analyze the diagnosis and treatment costs of patients with early and late-stage breast cancer, and to provide a basis for clinical diagnosis, treatment, and health policy formulation. Methods A retrospective review was conducted of 323 female breast cancer patients admitted to the First Affiliated Hospital of Baotou Medical College between August 2020 and October 2024. The study analyzed basic patient information, clinical treatment details, and medical expenses to compare diagnostic and treatment costs between early-stage and advanced-stage breast cancer patients. Results The 323 breast cancer patients ranged in age from 25 to 90 years old [(53.34±10.19) years], including 279 early-stage cases(86.38%) and 44 advanced-stage cases(13.62%); The total treatment costs amounted to 38 246.92(range: 23 211.46, 66 060.00) yuan per case. Early-stage patients incurred costs of 37 069.00(range: 23 675.73, 60 250.17) yuan per case, while advanced-stage patients incurred costs of 50, 926.59(20 544.98, 96 406.90) yuan per case. After reimbursement by urban employee medical insurance, the financial burden borne by advanced breast cancer patients was 11 471.27(8 089.30, 14 853.25) yuan per case, with direct medical costs accounting for 20.1% of the annual per capita disposable income. The economic burden for early-stage breast cancer patients was lower, at 8 288.48(7 289.85, 9 287.12) yann per case. After reimbursement by urban resident medical insurance, the economic burden borne by advanced breast cancer patients remained relatively heavy at 22 942.55(16 178.60, 29, 706.50) yuan per case, with direct medical costs accounting for 40.2% of annual per capita disposable income. Early-stage breast cancer patients faced an economic burden of 16 576.97(14 579.71, 18 574.23) yuan per case. If the patients paid out-of-pocket, the economic burden borne by late-stage breast cancer patients accounted for 134.1% of the annual per capita disposable income, and that for early-stage breast cancer patients accounted for 96.9% of the annual per capita disposable income. Conclusion The proportion of breast cancer diagnosis and treatment costs to per capita disposable income is relatively high. In the future, it is necessary to strengthen the prevention and control of breast cancer to alleviate the economic burden on patients.
[1]WHO. Global cancer observatory:cancer today, breast[EB/OL]. https：//gco. iarc. who. int/media/globocan/factsheets/cancers/20-breast-fact-sheet.pdf.
[2]WHO. Global cancer observatory:cancer today, China[EB/OL]. https：//gco. iarc. who. int/media/globocan/factsheets/populations/160-china-fact-sheet.pdf.
[3]中华人民共和国国家卫生健康委员会.乳腺癌诊疗指南（2022年版）[J].中国合理用药探索，2022,19(10):1-26. DOI:10.3969/j.issn.2096-3327.2022.10.001.
[4]Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients:ESMO Clinical Practice Guidelines[J].Ann Oncol, 2014, Suppl 3:iii124-137. DOI:10.1093/annonc/mdu103.
[5]Lee S, Olvera RG, Shiu-Yee K, et al. Short-term and long-term financial toxicity from breast cancer treatment:a qualitative study[J]. Support Care Cancer, 2023, 32(1):24. DOI:10.1007/s00520-023-08199-z.
[6]中国抗癌协会，国家肿瘤临床医学研究中心（天津医科大学肿瘤医院）.中国女性乳腺癌筛查指南[J].中国肿瘤临床，2019,46(9):430-432. DOI:10.3969/j.issn.1000-8179.2019.09.572.
[7]陈文婕，董玮琪，乔丽颖，等. 2015年内蒙古自治区女性乳腺癌发病与死亡情况及2010—2015年趋势分析[J].中国肿瘤，2020,29(10):736-743. DOI:10.11735/j.issn.1004-0242.2020.10.A004.
[8]包头市统计局.包头市2024年国民经济和社会发展统计公报[N].包头日报，2025-04-16(008). DOI:10.28037/n.cnki.nbtbr.2025.000834.
[9]Dvortsin E, Gout-Zwart J, Eijssen EL, et al.Comparative cost-effectiveness of drugs in early versus late stages of cancer; review of the literature and a case study in breast cancer[J]. PLoS One, 2016, 11(1):e0146551. DOI:10.1371/journal.pone.0146551.
[10]张俊清，路晨琳，黄梦晓，等.基于决策树模型的乳腺癌患者住院费用分析[J].中国慢性病预防与控制，2025,33(11):840-845. DOI:10.16386/j. cjpccd. issn. 1004-6194.20241206.0974.
[11]Lee KL, Eniu A, Booth CM, et al. Financial toxicity and breast cancer:why does it matter, who is at risk, and how do we intervene?[J]. ASCO Educational Book,2025, 45(3):e473450. DOI:10.1200/EDBK-25-473450.
[12]Çeli KY，Çeli K SŞ，Sarıköse S, et al. Evaluation of financial toxicity and associated factors in female patients with breast cancer:a systematic review and meta-analysis[J]. Support Care Cancer, 2023, 31(12):691. DOI:10.1007/s00520-023-08172-w.
[13]Jing J, Feng R, Zhang X, et al. Financial toxicity and its associated patient and cancer factors among women with breast cancer:a single-center analysis of low-middle income region in China[J]. Breast Cancer Res Treat,2020, 181(2):435-443. DOI:10.1007/s10549-020-05632-3.
[14]Rubagumya F, Wilson B, Manirakiza A, et al. Financial toxicity:unveiling the burden of cancer care on patients in Rwanda[J]. Oncologist, 2024, 29(3):e345-e350.DOI:10.1093/oncolo/oyad291.
[15]Veenstra CM, Wallner LP, Jagsi R, et al. Long-term economic and employment outcomes among partners of women with early-stage breast cancer[J]. J Oncol Pract,2017, 13(11):e916-e926. DOI:10.1200/JOP. 2017.023606.
[16]邹潘琳，林丽桑，谢宝缘，等.乳腺癌化疗患者经济毒性现状及影响因素[J].吉林医学，2024,45(11):2759-2763. DOI:10.3969/j.issn.1004-0412.2024.11.048.
[17]Fitzgerald SP. Breast-cancer screening:tiewpoint of the IARC working group[J]. N Engl J Med, 2015, 373(15):1479. DOI:10.1056/NEJMc1508733.
[18]Sun L, Legood R, Sadique Z, et al. Cost-effectiveness of risk-based breast cancer screening programme, China[J]. Bull World Health Organ, 2018, 96(8):568-577.DOI:10.2471/BLT.18.207944.
[19]Wang J, Greuter MJW, Zheng S, et al. Assessment of the benefits and cost-effectiveness of population-based breast cancer screening in urban China:a model-based analysis[J]. Int J Health Policy Manag, 2022, 11(9):1658-1667. DOI:10.34172/ijhpm.2021.62.
[20]岳璐，董铭洁，赵雪莲，等.中国乳腺癌预防控制现状、问题及应对策略[J].中国公共卫生，2025,41(12):1527-1531. DOI:10.11847/zgggws1146382.
基本信息:
DOI：10.13455/j.cnki.cjcor.113494-20251227-0445
中图分类号:R737.9;R1
引用信息:
[1]王志鹏,马庆庆,王雅楠,等.323例早期和晚期乳腺癌患者的诊疗费用经济学评价[J].中国肿瘤临床与康复,2026,33(02):115-123.DOI:10.13455/j.cnki.cjcor.113494-20251227-0445.
基金信息:
内蒙古自治区科技计划项目（2021GG0401）~~